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Berberine produces antidepressant-
like effects in ovariectomized mice
Jie Fan1, Bingjin Li1, Tongtong Ge1, Zhuo Zhang2, Jiayin Lv2, Jing Zhao1, Pu Wang3, Wei Liu1, 
Xuefeng Wang1, Katarzyna Mlyniec4 & Ranji Cui1
Berberine has been reports to have antidepressant-like effects. However, it is seldom known whether 
berberine produces antidepressant-like effects in ovariectomized mice, which exhibit depressive-like 
responses. To examine the antidepressant-like effects of berberine in ovariectomized mice, behavioral 
tests were conducted, including the forced swimming test and the open field test. To elucidate the 
mechanisms, levels of BDNF, phosphorylated CREB and phosphorylated eEF2 were analyzed by 
western blotting, and c-Fos induction was examined by immunohistochemistry. In the forced swimming 
test, berberine decreased the immobility time in a dose-dependent manner, reversing the depressive-
like effect observed in ovariectomized mice, and this effect was blocked by the 5-HT2 antagonist 
ketanserin. In addition, western blotting indicated that BDNF and peEF2 in the hippocampus, 
but not pCREB/CREB in the frontal cortex, were affected by berberine treatment. Furthermore, 
immunohistochemistry demonstrated that the reduction in c-Fos induced by ovariectomy were greater 
after berberine treatment. Ketanserin also antagonized the effect of berberine on the c-Fos expression. 
Our findings suggest that berberine exerts antidepressant-like effects in ovariectomized mice, and 
5-HT2 receptor activation may be partially related to the antidepressant-like effects of the berberine by 
BDNF-CREB and eEF2 pathways.
Depression is the most common mental disorders in humans. Although two-thirds of patients recover from a 
depressive episode spontaneously, the remaining one-third cannot recover without antidepressant treatment1–3. 
Many antidepressant treatments are currently available, but they are not effective in all individuals, Furthermore, 
they are associated with adverse effects in many individuals. Therefore, the present study aimed to identify a 
new potential antidepressant drug with fewer side effects. In our previous study the total Fuzi alkaloid extract 
produces antidepressant-like effects4. Therefore, in this study, the antidepressant-like effect of berberine, another 
specific alkaloid, was investigated in ovariectomized (OVX) mice.
Berberine is an isoquinoline quaternary alkaloid that can be exacted from many medicinal plants5, 6. It has sev-
eral known pharmacological effects7–16. In particular, berberine inhibits corticosterone-induced depressive-like 
behavior in mice, which may be due to up-regulates BDNF expression13. Another report demonstrated that ber-
berine could exert antidepressant-like action in both the forced swimming test and the tail suspension test with 
elevated 5-HT/NE/DA levels14. However, the antidepressant-like effect of berberine in OVX mice has rarely been 
studied.
Eukaryotic elongation factor 2 (eEF2) is involved in the actions of rapid-onset antidepressants17, 18. It has been 
reported that rapid-onset antidepressant-like behavior is mediated by the decreased phosphorylation of eEF2 
and the increased translation of BDNF17, 18. Other studies have demonstrated that the CREB and phosphorylated 
CREB (pCREB) levels are upregulated in rodent brains during antidepressant treatment19–21. The BDNF-CREB 
pathway is a well-established antidepressant pathway that plays a critical role in antidepressant action20, 22, 23. 
Furthermore, it is has been reported that antidepressant treatment increase c-Fos expression24–27. Therefore, the 
present study was aimed to examine the antidepressant-like effect of berberine in OVX mice. The effect of berber-
ine on the BDNF-CREB-eEF2 pathway was analyzed, including signaling mediated by pCREB and phosphoryl-
ated eEF2 (peEF2), which was assessed using the pCREB/CREB and peEF2/eEF2 ratios. Immunohistochemical 
staining of c-Fos was used to test the antidepressant-like action of the berberine.
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Results
Effect of repeated berberine treatment on body weight. Repeated administration of berberine 
or imipramine did not change the body weight of OVX mice, nor did any of the other treatments. A two-way 
ANOVA revealed no significant effect of drug treatment (P > 0.05), and no significant interaction between the 
treatment and time (P > 0.05) (Fig. 1).
Effect of repeated berberine treatment on locomotor activity. Figure 2a and b reveal that berberine 
did not affect locomotor activity or rearing (locomotor activity: P > 0.05; rearing: P > 0.05). This indicates that 
general changes in activity were not responsible for the differences in immobility time induced by berberine in 
the forced swim test.
Effect of repeated berberine treatment on immobility time. Figure 3 shows that immobility time 
was significantly change across treatment groups (treatment effect: P < 0.001). Immobility time was increased 
in OVX mice compared to the sham treatment group (P < 0.01), and berberine dose-dependently decreased 
the ovariectomy-induced increase in immobility time. Berberine (10.0 mg/kg) produced a marked reduction 
compared to the OVX only group (P < 0.01). Interestingly, ketanserin (5.0 mg/kg) reversed the effect of berberine 
on immobility time (P < 0.001). This reversal normalized immobility compared with the sham control group. 
Imipramine significantly inhibited the immobility time compared with the OVX only group (P < 0.01). However, 
ketanserin alone had no effect.
Effect of the repeated berberine treatment on the pCREB/CREB ratio. The western blotting results 
for pCREB and CREB, with averages for each treatment group, are shown in Fig. 4. Differences in the pCREB/
CREB ratios were observed in the frontal cortex (P < 0.05), but not in the hippocampus (P > 0.05). Ovariectomy 
reduced the pCREB/CREB ratio (P < 0.05). This effect was reversed by berberine (P < 0.05), whereas the berber-
ine/ketanserin group was not much different from the OVX-only group. Imipramine produced an elevation in the 
pCREB/CREB ratios in the hippocampus and the frontal cortex (P < 0.05).
Figure 1. Body weight in subjects from all groups over the 7-day course of pharmacological treatment. 
sham-treated mice (sham) and ovariectomized (OVX) mice treated with saline (OVX + Sal), 5 mg/kg 
berberine (OVX + Ber 5 mg/kg), 10 mg/kg berberine (OVX + Ber 10 mg/kg), 10 mg/kg berberine + ketanserin 
(OVX + 10 mg/kg Ber + Ket, ketanserin only (OVX + Ket 5 mg/kg), or imipramine (OVX + Imi 30 mg/kg).
Figure 2. Locomotor behavior and rearing behavior in the open field. (A) Locomotor behavior (number of line 
crosses) in the open field. (B) Rearing behavior (frequency) in the open field. Group conditions are indicated by 
abbreviations, and doses by numbers: Sham (sham treatment), OVX (ovariectomy), Ber (berberine, 5 or 10 mg/
kg), Ket (ketanserin, 5 mg/kg) and Imi (imipramine, 30 mg/kg).
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Effect of the repeated berberine treatment on the BDNF protein level. Substantial differences 
in the levels of BDNF (normalized to β-actin levels) were observed across treatment groups in both the frontal 
cortex (P < 0.001) and the hippocampus (P < 0.05), as shown in Fig. 5. Ovariectomy reduced the BDNF levels in 
both the hippocampus (P < 0.01) and the frontal cortex (P < 0.001). Berberine normalized the BDNF levels in the 
hippocampus (P < 0.01 vs. OVX alone, Tukey’s HSD) and this effect was reversed by ketanserin, which was not 
different from the OVX group. Imipramine did not affect the BDNF levels in either the hippocampus or frontal 
cortex
Effect of the repeated berberine treatment on the peEF2/eEF2 ratio. The effect of the repeated 
berberine treatment on the peEF2/eEF2 ratios is shown in Fig. 6. There was a significant change across treatment 
groups in the hippocampus (P < 0.05), but not in the frontal cortex (P > 0.05). In both regions there were small 
increases in the peEF2/eEF2 ratio after ovariectomy, although neither of these effects was statistically significant 
in post hoc comparisons. In the frontal cortex, berberine treatment had a tendency to increase the peEF2/eEF2 
ratio, which was significantly different from the sham control, but not the OVX alone group. Ketanserin did not 
affect the frontal cortex. In the hippocampus, berberine reversed the slight increase observed in OVX alone mice 
Figure 3. Duration of immobility time (s) in the forced swim test. Group conditions are indicated by 
abbreviations, and doses by numbers: Sham (sham treatment), OVX (ovariectomy), Ber (berberine, 5 or 
10 mg/kg), Ket (ketanserin, 5 mg/kg) and Imi (imipramine, 30 mg/kg). Symbols represent significant post 
hoc comparisons: Tukey’s HSD, #P < 0.05 vs. sham, **P < 0.05 vs. OVX, @P < 0.05 vs. OVX + Ber 10 mg/kg, 
&&P < 0.01 vs. OVX.
Figure 4. Representative western blots for CREB and pCREB. The frontal cortex (FC; left) and the 
hippocampus (HP; right). Figures represent the pCREB/CREB ratios in the FC and HP. Group conditions are 
indicated by abbreviations and doses by numbers: Sham (sham treatment), OVX (ovariectomy), Ber (berberine, 
5 or 10 mg/kg), Ket (ketanserin, 5 mg/kg) and Imi (imipramine, 30 mg/kg). Symbols represent significant post 
hoc comparisons: Tukey’s HSD, #P < 0.05 vs. sham, **P < 0.05 vs. OVX only.
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(Tukey’s HSD, P < 0.05 vs. OVX alone). This effect was slightly reversed by ketanserin treatment. Imipramine had 
no effect on the peEF2/eEF2 ratio.
Effect of the repeated berberine treatment on the c-Fos expression. Representative examples of 
c-Fos stained hippocampal sections are shown in Fig. 7a, and cell counts are depicted in Fig. 7b and c. There were 
significant differences across treatment groups in both frontocortical and hippocampal subregions. In fronto-
cortical subregions, ovariectomy reduced the c-Fos level in the cingulate cortex (Cg1), the infralimbic cortex 
(IL) and the prelimbic cortex (PRL). In Cg1, this effect was inhibited by berberine (one-way ANOVA: P < 0.01; 
P < 0.05 vs. OVX alone; Tukey’s HSD), an effect that was antagonized by ketanserin (not significantly different 
from OVX-alone mice but different from OVX/berberine-treated mice, P < 0.05). Berberine and ketanserin did 
not remarkably change the effects of OVX in the IL or PRL. Imipramine reversed the effects of ovariectomy in 
Cg1 and PrL (P < 0.05 vs. OVX alone) but not the IL. Significant differences in c-Fos were found in the dentate 
Figure 5. Representative western blots for BDNF and β-actin. The frontal cortex (FC; left) and the 
hippocampus (HP; right). Figures represent the BDNF levels (normalized to β-actin) in the FC and HP. Group 
conditions are indicated by abbreviations and doses by numbers: sham (sham treatment), OVX (ovariectomy), 
Ber (berberine, 5 or 10 mg/kg), Ket (ketanserin, 5 mg/kg) and Imi (imipramine, 30 mg/kg). Symbols represent 
significant post hoc comparisons: Tukey’s HSD, #P < 0.05 vs. sham, **P < 0.05 versus OVX only.
Figure 6. Representative western blots for peEF2 and eEF2. The frontal cortex (FC; left) and the hippocampus 
(HP; right). Figures represent the peEF2/eEF2 ratios in the FC and HP. Group conditions are indicated by 
abbreviations and doses by numbers: Sham (sham treatment), OVX (ovariectomy), Ber (berberine, 5 or 
10 mg/kg), Ket (ketanserin, 5 mg/kg) and Imi (imipramine, 30 mg/kg). Symbols represent significant post hoc 
comparisons: Tukey’s HSD, *P < 0.05 vs. OVX only.
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gyrus of the hippocampus (P < 0.001). Ovariectomy produced a marked reduction in c-Fos only in the dentate 
gyrus (P < 0.05). This effect was reversed by berberine (P < 0.05 vs. OVX alone, Tukey’s HSD) and ketanserin (not 
significantly different from OVX alone but different from OVX/berberine-treated mice, P < 0.05). Imipramine 
increased the c-Fos expression in all areas of the frontal cortex subregions except the CA4 region compared with 
OVX alone (P < 0.05 vs. OVX-alone treated mice, Tukey’s HSD).
Discussion
Berberine has anti-inflammatory actions27–31. However, although it is a constituent of many Chinese traditional 
medicines, its other potential medical applications remain to be addressed. Our findings indicate that berberine 
may have antidepressant effects, based on its ability to decrease the immobility time in the forced swimming test 
in OVX mice without affecting body weight. These results are consistent with previous report indicating that 
ovariectomy increases the immobility in the forced swimming test, and that Fuzi total alkaloid extract exerted 
antidepressant-like effects in this model4. In addition, there were no body weight changes between OVX animals 
and sham animals 7 days after ovariectomy, but there were changes 21 days after ovariectomy (data not shown 
here). Therefore, these results are consistent with other reports that OVX animals gain body weight compared 
with shams. Shen et al. reported that berberine administration for 3 weeks attenuates corticosterone-induced 
depressive-like behavior in mice13. These results also reveal that the effect of berberine may be faster in ovariect-
omized mice than in corticosterone-treated mice.
The mechanisms that might underlie these effects of berberine were unknown. Therefore, several possible 
mechanisms were explored in the present experiments. In western blot studies, berberine increased the pCREB/
Figure 7. c-Fos-positive cells in frontal cortex and hippocampus. (A) Representative sections through the 
dentate gyrus (inset: greater magnification near the tip of the dentate), showing c-Fos stained cells (dense 
brown nuclear staining) and counterstaining with neutral red. (B) The number of c-Fos positive cells in the 
subregions of the frontal cortex: cingulate cortex (Cg1), infralimbic cortex (IL), and prelimbic cortex (PrL). 
(C) The number of c-Fos positive cells in the subregions of the hippocampus: cornu ammonis 1–4 (CA1-CA4) 
and dentate gyrus (DG). Group conditions are indicated by the following letters and abbreviations: (A) Sham, 
sham treatment; (B) OVX, ovariectomy only; (C) OVX + Ber, ovariectomy and berberine, 10 mg/kg; (D) 
OVX + Ber + Ket, ovariectomy, berberine, 10 mg/kg, and ketanserin, 5 mg/kg; (E) OVX + Ket, ovariectomy 
and ketanserin, 5 mg/kg); and (F) OVX + Imi, ovariectomy and imipramine, 30 mg/kg. Symbols represent 
significant post hoc comparisons: Tukey’s HSD, *P < 0.05, **P < 0.01 vs. Sham; #P < 0.05, ###P < 0.001, vs. OVX 
only; @P < 0.05 vs. OVX + Ber + Ket.
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CREB ratio in the frontal cortex, which is reduced by ovariectomy. This is in agreement consistent with previ-
ous reports indicating antidepressant treatments increase in CREB phosphorylation32. Furthermore, it has been 
reported that the immunoreactivity for both CREB and pCREB are significantly decreased in the patient frontal 
cortex with major depressive disorder33. These effects are similar to those of an ovariectomy here. On this basis 
the effects of berberine on CREB pathway were examined in the frontal cortex. These findings suggest that the 
modulation of CREB signaling may be partially responsible for the behavioral effects of berberine observed here. 
Interestingly, there was no marked change in the pCREB/CREB ratios in the hippocampus, whereas imipra-
mine altered the pCREB/CREB ratio. The details of these mechanisms that have been initially elucidated here, 
require further investigation. In addition, hypothalamic-pituitary-adrenal axis (HPA axis) activation and BDNF 
are related to the antidepressant-like effect of berberine in corticosterone-treated mice13. However, the role of the 
HPA axis in the berberine-induced antidepressant effect in ovariectomized mice also needs further investigation.
Other potential mechanisms may certainly be involved, including those related to fast-acting antidepres-
sants, which have been investigated recently18. Accordingly, the effects of berberine on the BDNF-eEF2 pathway 
were also examined. The level of BDNF was reduced in OVX mice in the hippocampus and the frontal cor-
tex. Berberine did not affect reductions in the frontal cortex, but it reversed these changes in the hippocampus. 
Moreover, these changes in the level of BDNF in the hippocampus were accompanied by reductions in the peEF2/
eEF2 ratio after ovariectomy. Similarly, the herbal medicine Yueju rapidly reduces the peEF2, which leads to 
the desuppression of BDNF synthesis18. Autry et al. found that rapid antidepressant-like behavior is regulated 
by inhibited peEF2 and enhanced BDNF translation17. Subchronic treatment with serotonin 5-HT2C receptor 
antagonists may also produce faster-acting antidepressant effects than many currently available antidepressants34. 
This suggestion was based on effects seen in the chronic forced swimming, chronic mild stress and olfactory 
bulbectomy models. These actions were linked to the activation of mTOR, BDNF, and eEF2 in the frontal cortex. 
Subchronic treatments also reversed chronic mild stress-induced neuronal atrophy. Similar effects on eEF2 were 
observed in the frontal cortex of OVX mice. Moreover, many of the effects here were shown to be 5-HT-mediated.
5-HT2 receptors play an important role in depression. Zen et al. reported that ferulic acid exerted an 
antidepressant-like effect in mice, and this effect was blocked by the 5-HT2 receptor antagonist ketanserin. 
However, the administration of ketanserin alone did not affect the tail suspension test35. Therefore, in this study 
we also examined whether the antidepressant-like effect of berberine was blocked in the forced swimming test. 
In this study ketanserin partially reversed the effects of berberine on pCREB in the frontal cortex, and BDNF in 
the hippocampus, although it did not appear to influence eEF2. In addition, ketanserin antagonized the effects 
of berberine on the reductions of c-Fos induced by ovariectomy in the dentate gyrus and cingulate cortex. These 
results parallel the effects of ovariectomy and these drugs in the forced swimming test, in which ketanserin antag-
onized the immobility-decreasing effects of berberine on the elevations in immobility time induced by ovariec-
tomy. The effects of ovariectomy have previously been linked to serotonergic alterations, including decreases 
serotonin 5-HT2A receptors mRNA and protein in rats36, 37, and increased 5-HT2A receptor binding after estrogen 
replacement therapy in postmenopausal women38, 39. Kulkarni and Dhir (2007)40 reported that berberine may 
have antidepressant effects in standard models of behavioral despair, including the forced swimming test and the 
tail suspension test, in otherwise untreated mice. It was suggested that increased levels of monoamines, perhaps, 
changes in their effects on the nitric oxide levels, were associated with these actions.
In this study, berberine influenced the BDNF-eEF2 pathway in the hippocampus, and CREB signaling in the 
frontal cortex, leading to antidepressant effects in the ovariectomy model of depression. Furthermore, the actions 
of berberine may be faster than the actions of 2 to 4 weeks of administration of a SSRI or SNRI. In both the hip-
pocampus and the frontal cortex, there were differences found in c-Fos activation, with reductions after ovariec-
tomy, and berberine was able to reverse these reductions. Moreover, these effects were antagonized by ketanserin, 
which indicated that 5-HT2 receptors may partially be involved in these effects. Therefore, berberine should be 
further explored as a potential new antidepressant treatment.
Materials and Methods
Animals. Female ICR mice (from 6 to 10 weeks) were purchased from Jilin University (Changchun, China). 
Mice were kept in plastic cages (25.5 cm × 15 cm × 14 cm), and maintained in standard laboratory conditions 
(23 ± 1 °C, a 12 h light dark cycle). The mice were allowed free access to food and water. The surgical procedure 
for the ovariectomy followed the method outlined by Liu et al.4, in which the bilateral ovarian resection was per-
formed (9 weeks). Briefly, each mouse (female) was anesthetized with chloral hydrate (10%)41. Following an small 
incision made with a pair of forceps and scissors, the ovary was obtained from the opening in the musculature. 
A ligature was put around fallopian tube and each ovary before the ovaries, and periovarian fat, were bilateral 
resection. Sham-operated animals used the same procedure as the OVX mice but without ovarian resection. 
Behavioral studies were performed during the light phase.
All experiments were carried out in accordance with the Guide for Animal Experimentation of Jilin University. 
The protocol was approved by the Jilin University Institutional Animal Care and Use Committee.
Drugs. Berberine (5.0 and 10.0 mg/kg) was purchased from the National Institutes for Food and Drug Control 
(Beijing, China). Imipramine and ketanserin hydrochloride were purchased from Sigma Aldrich (St. Louis, MO, 
USA). All drugs were dissolved in saline.
Experimental Design. For the behavioral portion of the study, Sham ovariectomized animals served as 
control subjects for the effects of OVX. There were 6 OVX/drug treatment groups, including sham, OVX/saline, 
OVX/berberine, OVX/berberine/ketanserine, OVX/ketanserine and OVX/imipramine groups. In the behavioral 
study, two groups of subjects were treated for 7 days with berberine only (5.0 or 10.0 mg/kg i.p.). The OVX/ber-
berine/ketanserine group of mice was treated with berberine (10 mg/kg i.p.) and ketanserin (5.0 mg/kg i.p.). The 
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OVX/ketanserine and OVX/imipramine group served as a positive control, and the animals received imipramine 
(30 mg/kg, i.p.) as previously reported4. Ketanserin was administered 30 min after berberine administration in 
the berberine/ketanserin group. The dose levels of the berberine and ketanserine used were based on the previous 
reports14, 42.
For the western blotting experiments, all animals were tested behaviorally, and tissues were collected from 
the prefrontal cortex and hippocampus. In addition, a separate experiment was performed with OVX mice that 
were treated with imipramine as a positive control. All mice were weighed daily throughout the drug treatments.
Open field test. Exploratory behavior was performed in an open field test prior to forced swimming test. The 
test was performed using Hall’s open-field apparatus38, and followed the same criterion with slight modification. 
Mice were put separately in a square acrylic apparatus (48.8 cm × 48.8 cm with 16 cm high walls) with the gray 
floor, (divided into 16 equal squares). Open field was assessed as the number of grid lines crossed with all of four 
paws. The frequency of rearing was also measured. The duration of the test was 6 min.
Forced swimming test. The forced swimmg test was conducted 24 h after the last treatment of drug as pre-
viously reported39. It was performed in a cylindrical container (25 cm high, 11 cm in diameter) filled with water 
to 20 cm (25 ± 1 °C). After the test, all mice were dried using a towel and kept warm before going back to home 
cages. The times of immobility were recorded during swim test (6 min) by an observer blind to treatment condi-
tions, using a captured video of the test. The immobility duration during the last 4 min of the trial was calculated.
Western blot. Mice were decapitated immediately after forced swimming. The frontocortical and hippocam-
pal tissue was collected, and the protein was extracted using standard procedures. Tissue lysates were imme-
diately assessed for the levels of BDNF, eEF2, CREB and pCREB levels using western blot. After separation on 
10% SDS-PAGE gels, the proteins were transferred to polyvinylidene difluoride (PVDF) membranes by elec-
troblotting. BDNF, eEF2, phosphoeEF2, CREB, pCREB and β-actin were immunostained by initial incubation 
with the following primary antibodies: BDNF (1:1000, rabbit polyclonal; Santa Cruz Bio, CA, USA, #sc546), eEF2 
(1:1000, rabbit polyclonal; Cell Signaling Technology; #2332), peEF2 (1:1000, rabbit polyclonal; Cell Signaling 
Technology; phospho-eEF2 (Thr56)#2331), phosphoCREB-ser133 (1:1000, rabbit polyclonal; Cell Signaling, 
#CST9197S), CREB (1:1000, rabbit monoclonal; Cell Signaling, #CST9191S) and β-actin (1:2000, mouse mon-
oclonal; Transgen Biotech, #HC201). After the membranes were washes using TBST buffer solution, the respec-
tive peroxidase-labeled secondary antibodies (anti-rabbit: 1:400; Protein Tech, #SA00001-2; anti-mouse: 1:5000; 
ZSBG-Bio, #ZB2305) were used for their incubation. Specific band densities were quantified using the Image J 
software, and the ratio of intensities of pCREB/CREB, peEF2/eEF2 and BDNF/β-actin from the same homogenate 
were calculated42.
C-Fos immunohistochemistry. C-Fos immunohistochemistry was performed as reported by our group26. 
Briefly, all mice were first deeply anesthetized with chloral hydrate (400 mg/kg, i.p.), and brain perfusion with ice 
cold PBS, followed by 4% paraformaldehyde in PBS was performed. After removal, brains were post-fixed with 
30% sucrose. Serial coronal sections (30 µm thick) from different treatment groups were processed in parallel to 
minimize variation in the immunohistochemical labeling. Free floating sections incubated using 0.6% solution of 
hydrogen peroxide containing PBS. After rinsing again with PBS buffer, the sections incubated with rabbit poly-
clonal c-Fos antibody (1:1000, Santa Cruz Biotechnology, #sc-52) solution containing 0.3% Triton X-100, 0.05% 
sodium azide, and 2% normal goat serum for 72 h at 4 °C. The sections were then whashed and incubated using a 
secondary antibody (1:400, biotinylated goat anti-rabbit IgG (Vector Laboratories) at dilution in PBS buffer con-
taining 0.3% Triton X-100 for 75 min at room temperature. After rinsing in PBS buffer, the sections were replaced 
by PBS buffer containing 0.4% avidin-biotinylated horseradish peroxidase complex (Vector Laboratories) for 
another 75 min. Following washes in PBS buffer and 0.2 M sodium acetate solution, pH 6.0, the reaction was 
continued using the glucose oxidase-diaminobenzidine-nickel method. The sections were finally washed by 0.2 M 
sodium acetate solution. Thereafter, the sections were moved to chrome-alum-gelatin-coated slides. We coun-
terstained air-dry the section with neutral red, dehydrated using a graded alcohol series, cleared in xylene and 
cover slipped. Bilateral c-Fos counting was conducted on a minimum of three representative sections per level in 
a blind fashion. The positive cells were counted under ×200 magnification from the hippocampus and prefrontal 
cortex. Separate counting was performed for the prefrontal subregions, the cingulate cortex (Cg1), the infralimbic 
cortex (IL) and the prelimbic cortex (PrL), according to the atlas of Franklin and Paxinos43. Separate counts in 
the hippocampus were performed in the dentate gyrus, and the CA1, CA2, CA3, and CA4 regions. Using light 
microscopy, c-Fos positive neurons were identified by dense brown nuclear staining, and captured with a Nikon 
digital camera (EcLipse 50i Microsope Nikon). The counting c-Fos was blind to experimental conditions. Brain 
regions were confirmed using the mouse brain atlas43. These counts were averaged for five to eight sections in each 
region for each animal.
Statistical analyses. All data are expressed as the mean ± S.E.M. We analyzed the data using a two- or 
one-way analysis of variance (ANOVA). A two-way ANOVA with drug treatment as the between-subjects factor 
and time as the within-subject factor, was used for the statistical analysis of the body weight data. A one-way 
ANOVA was used to probe behavioral, immunohistochemistry and western blot data. When significant differ-
ences were obtained, post hoc comparisons were performed using Tukey’s honestly significant difference test 
(Tukey’s HSD) to compare treatment groups and sham-treated animals, as well as OVX/berberine- and OVX/
berberine/ketanserin-treated animals. P-values less than 0.05 were considered significant. Student’s t-test was 
performed to make comparisons between the imipamine and control group in the western blotting44–46.
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